Transferrin Receptor Hijacking Delivers a 1,000-Fold Brain Exposure Leap for Oligonucleotides

One of this year's tours returned to the University of Nevada, Las Vegas (UNLV) Kirk Kerkorian School of Medicine, which first welcomed InfoComm attendees in 2024. While the five-story building itself hasn't changed, many of the technologies and workflows inside it have.

New research is drawing attention to a critical link between women’s reproductive health and long-term heart health, with studies suggesting that some common gynecological conditions may raise the risk of serious cardiovascular problems later in life.

Results from a late-stage clinical trial of the pill daraxonrasib offers new hope for a notoriously deadly disease, doctors say.

UNLV Kirk Kerkorian School of Medicine is being honored for the design and operation of its main building. The school says its the first academic institution in Nevada to get LEED Platinum certification from the U.S Green Building Council.

The 2026 Alzheimer disease drug development landscape highlights a growing shift toward diverse disease-modifying strategies, from amyloid and tau targeting to metabolic and neuroprotective approaches.

From training more doctors in Southern Nevada to finding money for transit programs, many of the topics that committees decided need lawmaker attention have been the subject of local coverage here in the valley.

The Kirk Kerkorian School of Medicine at UNLV has received LEED Platinum Certification for the operations and maintenance of its Medical Education Building, the highest tier in the world’s most widely used green building rating system, university officials said in a news release.

Fatal wrong-way crashes are increasing in Nevada, with Clark County accounting for the largest share of those deadly collisions, according to a new analysis from UNLV's Nevada Traffic Safety Research Center.

The extended-release oral combination of dextromethorphan-bupropion uses a different mechanism of action than antipsychotic medications, which clinicians sometimes prescribe for patients with Alzheimer's disease who also experience agitation. But whether the new medication will be used as a first-line treatment is up for debate.

UNLV appears several times on U.S. News & World’s Report’s new Best Global Universities rankings.

More than seven years of development, over $60 million in funding and a series of early clinical studies have led to this: Allyx Therapeutics is preparing for what may be the most consequential test in the New Haven-based biotech startup’s history.